Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Hagai Yavin

Cardiovascular Disease Chicago, IL Medical Doctor

NPI 1831771765 CMS profile 11422799

1725 W Harrison St Ste 358, Ste 358, Chicago, IL 60612

Open in the dashboard

General payments

$34,574

215 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hagai Yavin of Chicago, IL is reported in the CMS Open Payments database as having received $34,574 across 215 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,670 49
2024 General $15,537 61
2023 General $8,200 76
2022 General $5,167 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hagai Yavin
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Hagai Yavin were reported at $5,670. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Hagai Yavin Cardiovascular Disease median Middle half National median
2019 $0 $450 $127–$1,392 $163
2020 $0 $242 $77–$751 $114
2021 $0 $335 $101–$1,037 $132
2022 $5,167 $395 $121–$1,211 $149
2023 $8,200 $443 $136–$1,283 $160
2024 $15,537 $450 $136–$1,323 $164
2025 $5,670 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Biosense Webster, Inc. $14,225 24 payments
  2. Medtronic, Inc. $8,684 93 payments
  3. Biotronik Inc. $5,937 25 payments
  4. Abbott Laboratories $3,579 44 payments
  5. Boston Scientific Corporation $1,373 20 payments
  6. CardioFocus, Inc. $442 5 payments
  7. Atricure, Inc. $225 2 payments
  8. Volta Medical Inc $83 1 payment
  9. Philips Electronics North America Corporation $26 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Travel and Lodging $12,173 61 payments
  2. Food and Beverage $10,943 147 payments
  3. Consulting Fee $10,913 4 payments
  4. Education $546 3 payments
Products named General payments · program years 2022–2025
  1. Micra $2,251 23 payments
  2. Edora 8 DR-T $1,360 1 payment
  3. Acticor 7 VR-T DX $1,360 1 payment
  4. Solia $1,360 1 payment
  5. Rivacor 7 DR-T $1,360 1 payment
  6. BioMonitor $1,360 1 payment
  7. AVEIR $1,234 6 payments
  8. SelectSecure $1,174 16 payments
  9. ENSITE PRECISION $1,117 18 payments
  10. Carto 3 $513 9 payments
  11. Other $3,899 62 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

247

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$106,392

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

33.2%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 56 $80,301
Xarelto Rivaroxaban Brand 26 $23,497
Metoprolol Succinate Generic 108 $1,719
Amiodarone Hcl Generic 46 $846
Amlodipine Besylate Generic 11 $29

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$92,332

Medicare's payments for the services billed

Medicare patients

828

Average age 76

Services billed

1,523

417 women, 411 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 59%
Heart failure 58%
Atrial fibrillation 56%
Arthritis 54%
Diabetes 47%
Chronic kidney disease 46%
COPD 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

215 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record